Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Raphael Pharmaceutical Inc. (ESYE)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
16.4
|
M
| |
|
|
| Market cap: |
$49.1
|
k
| |
|
|
|
Net cash:
|
$72
|
k
| |
$0.00
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 |
| Revenues | 1.5 | 0.8 | 0.1 |
| Revenue growth | 95.7% | 649.5% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 |
| Gross profit | 1.5 | 0.8 | 0.1 |
| Gross margin | 100.0% | 100.0% | 100.0% |
| Research and development | 1.2 | 0.8 | 0.5 |
| General and administrative | 2.1 | 0.9 | 0.2 |
| EBIT | -3.2 | -1.6 | -0.7 |
| EBIT margin | -214.8% | -201.3% | -685.4% |
| Pre-tax income | 3.4 | 1.6 | 0.7 |
| Income taxes | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% |
| Net income | 3.4 | 1.6 | 0.7 |
| Net margin | 222.2% | 210.5% | 697.1% |
| |
| Diluted EPS | $0.23 | $0.15 | $0.08 |
| Shares outstanding (diluted) | 14.3 | 11.2 | 9.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|